Insight Molecular Diagnostics Inc. (IMDX) income statement
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.59−0.19 (-10.67%)
Close on Nov 18, 2026Market cap $52.03MP/E –Yield –
Insight Molecular Diagnostics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 48.3%
- Operating margin
- -3011.9%
- Net margin
- -2955.6%
- Return on equity, FY2025
- 229.6%
Financial strength
- Current ratio
- 2.00
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 172.6%
Valuation
- P/E ratio
- –
- Price to sales
- 31.16
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?